Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.
Data from the GUIDED study will be central to commercial payor discussions, a Medicare LCD reconsideration request, and eventually expansion into the primary care market.
The group recommends Myriad Genetics' EndoPredict, NanoString's Prosigna, and Genomic Health's Oncotype DX tests for guiding chemotherapy decisions if certain conditions are met.
At the conference, researchers presented data from a number of studies using molecular diagnostic tools to better characterize breast cancer recurrence and treatment outcomes.
